APA (7th ed.) Citation

Lang, W., Ai, Q., Zhang, W., Jiang, Q., He, Y., & Ouyang, M. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Lang, Wenwang, Qi Ai, Wenwen Zhang, Qinling Jiang, Yulong He, and Ming Ouyang. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A.

MLA (9th ed.) Citation

Lang, Wenwang, et al. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A.